Several clinical studies have tested the efficacy of insulin‐sensitizing TZDs in AD patients, mostly reporting failure to prevent or improve cognitive and functional decline in those suffering moderate‐to‐advanced AD. This evidence concerns the gene INS and Alzheimer disease.